FOR IMMEDIATE RELEASE
6 August 2004
Contact:
Daryl Risinger
Vice-President, Marketing, Inogen, Inc.
805.562-0511

SANTA BARBARA, CA – There is excitement in the air at the California headquarters of Inogen Corporation where production details are being finalized to begin shipping the Inogen One on October 1st, 2004.

In May, Inogen received clearance from the US Food and Drug Administration to begin marketing the Inogen One, taking another significant step forward in how oxygen therapy is provided to patients.

The revolutionary design of the Inogen One has created an entirely new product category of “independent” oxygen devices. Previously available technologies fall into one of two categories, portable or stationary; the Inogen One serves both needs.

“We couldn’t be more pleased with the response from the provider industry," said Kathy Odell, CEO of Inogen. "The Inogen One represents a concept providers have been waiting a long time to receive. What was hoped for is now reality.”

Inogen is currently finalizing an agreement with a national distribution partner and will soon announce details to the public.

Both oxygen patients and HME providers have a lot to look forward to with the offical introduction of the Inogen One. A truly portable concentrator, the Inogen One is one device that will replace many. More than a slight improvement over current technologies, the Inogen One will lead the industry in several key categories: the lightest weight concentrator, the longest battery life, the most sensitive oxygen conserver technology, and one of the quietest devices available.

The Inogen One seeks to redefine the patient experience by improving each aspect of the delivery of oxygen therapy. Notable patient-focused improvements include: a userfriendly LCD information display; large print, easy to read and understand product materials; and a family of accessory products that enhance the use of the Inogen One at home or away.

“It's hard to underestimate the importance of this moment for our industry,” said Vernon Pertelle, Corporate Director of Respiratory & HME Services at Apria Healthcare. “When Inogen first arrived on the scene, they were making some pretty bold promises and many of us had a wait and see attitude. Now that they've achieved 510(k), there are a lot more people who are paying really close attention -- and this presents an opportunity to change how we view oxygen therapeutics. This product provides one more component to the armamentarium of therapeutic products available for patients. In addition this device will assist patients who want to travel and give them the flexibility to be more mobile. (The Inogen One) will reduce oxygen deliveries and decrease delays associated with those deliveries either at home, for patients who travel by air, cruises or motor home and maintenance requirements may be substantially reduced through the use of this product.”

Since the first introduction of the Inogen One last year, there has been overwhelming demand from both patients and providers who continue to contact Inogen on a regular basis.

“To have a date that product will begin shipping is a major milestone,” says Odell. “We are excited to see the Inogen story continue to unfold. For now, we are anxious to begin meeting the needs of today's more mobile oxygen patient.”